Cube Labs Subsidiaries DTech, Adamas Biotech Secure Japanese Patent for Coronavirus Prevention Formulation

• DTech and Adamas Biotech secured a Japanese patent for a pharmaceutical composition targeting coronavirus prevention and treatment, including SARS-CoV-2.
• Patent No. 562753, titled “Catechin containing compositions and uses,” was published today; the invention already has patent protection in other international markets.
• The formulation combines a catechin-enriched hydrogel with an aqueous salt solution for potential oral, inhaled or mucosal administration.
• Cube Labs owns 51% of each subsidiary, with additional trust-held stakes of 9% in DTech and 4% in Adamas Biotech.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cube Labs S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20282-38-2026_TELEBORSA.pdf), on November 12, 2026, and is solely responsible for the information contained therein.